Immatics NV (Immatics NV) Debt-to-Equity : 0.07 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Immatics NV Debt-to-Equity?

Immatics NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.84 Mil. Immatics NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $13.96 Mil. Immatics NV's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $245.46 Mil. Immatics NV's debt to equity for the quarter that ended in Dec. 2023 was 0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Immatics NV's Debt-to-Equity or its related term are showing as below:

IMTX' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.08 Med: 0.07 Max: 0.41
Current: 0.07

During the past 6 years, the highest Debt-to-Equity Ratio of Immatics NV was 0.41. The lowest was -0.08. And the median was 0.07.

IMTX's Debt-to-Equity is ranked better than
66.6% of 1069 companies
in the Biotechnology industry
Industry Median: 0.15 vs IMTX: 0.07

Immatics NV Debt-to-Equity Historical Data

The historical data trend for Immatics NV's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immatics NV Debt-to-Equity Chart

Immatics NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.08

0.07

0.41

0.07

Immatics NV Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.07	0.08	0.08	0.07	0.07

Competitive Comparison of Immatics NV's Debt-to-Equity

For the Biotechnology subindustry, Immatics NV's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immatics NV's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immatics NV's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Immatics NV's Debt-to-Equity falls into.

Immatics NV Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Immatics NV's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.84	+	13.956)	/	245.457
	=	0.07

Immatics NV's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.84	+	13.956)	/	245.457
	=	0.07

Immatics NV (NAS:IMTX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Immatics NV Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Immatics NV's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Immatics NV (Immatics NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immatics NV (NAS:IMTX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

4A3:Germany

Address

Paul-Ehrlich-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.immatics.com

Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.